Browsing tag:


The World Health Organization has predicted over 20 million new cancer cases in 2015 worldwide. This seemingly unbelievable number is not only astonishing; it is also a dire warning from the WHO. With the future onslaught of patients needing cancer care and treatments, the WHO has been urging researchers to continue to develop new products[…]

Read More

In a world where about a third of the adult male in the global population smokes, it’s tough not to take notice of its negative impact on the society as a whole. According to the WHO, if the smoking trends do not ease up, one in every 6 adults will die of smoking-related illness (e.g.[…]

Read More

A recent study conducted by the Queens University Belfasts School of Pharmacy revealed the ability of the recombinant protein FKBPL to inhibit tumor growth by disrupting the blood supply to these tumors. This method of cancer treatment called neovascularization is certainly not new with several agents exhibiting the same mode of action already available in[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service